Date: 2015-03-04
Type of information: Company acquisition
Acquired company: SuppreMol (Germany)
Acquiring company: Baxter (USA - IL)
Amount: € 200 million
Terms: * On March 4, 2015, Baxter International and SuppreMol announced that Baxter has acquired SuppreMol for € 200 million (approximately $225M) before working capital and other adjustments. The acquisition includes SuppreMol\'s early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases, focusing on the modulation of Fc receptor signaling pathways, an immune target that could have broad applications in autoimmune disorders. In addition to the portfolio, Baxter also acquires and will continue to operate SuppreMol\'s operations in Munich .
Details: SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases. SuppreMol\'s pipeline includes lead candidate SM101, an investigational immunoregulatory treatment that has completed Phase 2a studies in idiopathic thrombocytopenic purpura and systemic lupus erythematosus (SLE). SM101\'s Phase 2a data, presented during the American College of Rheumatology\'s 2014 annual meeting, showed a dose response in multiple endpoints among patients with SLE treated with either one of two different doses of SM101 for six months. The pipeline also includes technologies with potential therapeutic applications in other autoimmune diseases as well as IgE-mediated allergic diseases.
Related: Allergic diseases Autoimmune diseases
